Table 3. The difference of the hypothyroidism reporting rate between sunitinib and sorafenib regarding female and male populations.
| Female | Male | |||
|---|---|---|---|---|
| Sunitinib | Sorafenib | Sunitinib | Sorafenib | |
| Hypothyroidism Reported | 119 | 18 | 138 | 35 |
| Hypothyroidism Not Reported | 5232 | 2470 | 10015 | 6376 |
| Ratio of Hypothyroidism Report (%) | 2.22 | 0.72 | 1.36 | 0.55 |
| Odds Ratio (95% CI) | 3.12 (1.90 − 5.14) | 2.51 (1.73 − 3.64) | ||
| P-value* | 3.32E-07 | 1.28E-07 | ||
* One-tailed Fisher’s exact test was performed for the higher rate of hypothyroidism for sunitinib compared to sorafenib.